Price
$20.27+2.63%Social Signal Score
Analyst Ratings
8 analystsRevenue
$302.00M+121.36%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Franco Stevanato
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 6,010
- Beta
- 0.75
- Country
- IT
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.16
Financials
Revenue
$302.00M+121.4%Net Income
$23.00M+214.0%EBITDA
$40.10M+62.2%Free Cash Flow
$-33.87MEPS (diluted)
$0.08+222.6%Shares Outstanding (diluted)
273.00M-7.4%Operating Expenses
$37.90MCash & Debt
$83.58MReturn of Capital
$0.00Dividend per Share
$0.06Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.14B | $134.28M | $0.49 |
| 2024 | $1.10B | $117.78M | $0.43 |
| 2023 | $1.09B | $145.63M | $0.55 |
| 2022 | $983.68M | $142.85M | $0.53 |
| 2021 | $843.92M | $134.32M | $0.53 |
| 2020 | $662.04M | $78.51M | $0.28 |
| 2019 | $536.54M | $39.20M | $0.15 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from STVN's reported EPS growth of 21.8% a year over 6 years.
- EPS in 5 years
- $1.32
- Implied price
- $46.15
- Return from $20.20
- 18.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $22.94 — today's price is already 12.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 30 | 35 | 40 | 45 |
|---|---|---|---|---|---|
| 11.8% | 1.2% | 5.0% | 8.3% | 11.2% | 13.9% |
| 16.8% | 5.8% | 9.7% | 13.1% | 16.2% | 19.0% |
| 21.8% | 10.3% | 14.4% | 18.0% | 21.2% | 24.0% |
| 26.8% | 14.8% | 19.1% | 22.8% | 26.1% | 29.1% |
| 31.8% | 19.3% | 23.8% | 27.7% | 31.1% | 34.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+100.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·20d ago·Positive
Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsgurufocus.com·38d ago·Negative
Stevanato Group SpA (STVN) Shares Fall 5.7% -- What GF Score of 87 Tells Investors On August 28, 2026, Stevanato Group SpA (STVN) shares fell 5.7%, closing at $21.03. The stock has experienced a volatile year, with a 52-week range of $12.89 to
View source ↗ - Newsmarketbeat.com·58d ago·Negative
Stevanato Group Q2 Earnings Call Highlights Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.18 per share
Typical surprise +9.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.16 vs $0.14beat
- Thu, May 7$0.13 vs $0.12beat
- Wed, Mar 4$0.21 vs $0.20beat
- Thu, Nov 6$0.16 vs $0.14beat
- Tue, Aug 5$0.12 vs $0.11beat
- Thu, May 8$0.11 vs $0.10beat
Estimates and results for STVN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STVN officers and directors.
- Bought
- —
- Sold
- $562k
0 trades
8 trades
- Stocchi Maurosold
- Santel Lucianosold
- Dal Lago Marcosold
- Magistretti Elisabettasold
- Balachandran Madhavansold
- Morel Donald E Jrsold
- Flynn Karensold
- Federici William Jsold
34 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in STVN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.